2023-07-252023-07-252004-01-29https://hdl.handle.net/20.500.14300/1000The Special Investigations Division of the House Committee on Government Reform investigated a significant drop in FDA enforcement actions against false and misleading drug advertising during the first two years of the Bush Administration. Despite FDA Commissioner Mark McClellan's promise of more aggressive enforcement in 2003, the report states enforcement actions continued to decline that year, and delays in responding to false and misleading advertisements increased. The division suggest a contrast between the Commissioner's commitment and the actual enforcement trends at the FDA.8 pagesenStaff ReportsHouseHouse Minority Staff Report3: Health321: Regulation of Drug Industry, Medical Devices, and Clinical Labshttps://web.archive.org/web/20051024194711/http://www.democrats.reform.house.gov/story.asp?ID=440&Issue=Prescription+Drugs108